Okyo Pharma Ltd Stock Performance
| OKYO Stock | USD 1.04 0.01 0.95% |
The company holds a Beta of 0.38, which implies possible diversification benefits within a given portfolio. As returns on the market increase, OKYO Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding OKYO Pharma is expected to be smaller as well. At this point, OKYO Pharma has a negative expected return of -0.13%. Please make sure to check OKYO Pharma's treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day typical price , to decide if OKYO Pharma performance from the past will be repeated at some future point.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days OKYO Pharma Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
1 | OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain | 10/16/2024 |
2 | H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares - Investing.com | 10/24/2024 |
| Begin Period Cash Flow | 4 M |
OKYO |
OKYO Pharma Relative Risk vs. Return Landscape
If you would invest 120.00 in OKYO Pharma Ltd on August 30, 2024 and sell it today you would lose (16.00) from holding OKYO Pharma Ltd or give up 13.33% of portfolio value over 90 days. OKYO Pharma Ltd is currently does not generate positive expected returns and assumes 4.4543% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than OKYO, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
OKYO Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OKYO Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OKYO Pharma Ltd, and traders can use it to determine the average amount a OKYO Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0298
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OKYO |
Estimated Market Risk
| 4.45 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OKYO Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OKYO Pharma by adding OKYO Pharma to a well-diversified portfolio.
OKYO Pharma Fundamentals Growth
OKYO Stock prices reflect investors' perceptions of the future prospects and financial health of OKYO Pharma, and OKYO Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OKYO Stock performance.
| Return On Equity | -29.69 | ||||
| Return On Asset | -2.92 | ||||
| Current Valuation | 33.7 M | ||||
| Shares Outstanding | 33.84 M | ||||
| Price To Book | 14.11 X | ||||
| Gross Profit | (3.6 M) | ||||
| EBITDA | (15.74 K) | ||||
| Net Income | (16.8 M) | ||||
| Cash And Equivalents | 2.06 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 7.42 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.18) X | ||||
| Cash Flow From Operations | (9.49 M) | ||||
| Earnings Per Share | (0.57) X | ||||
| Market Capitalization | 36.54 M | ||||
| Total Asset | 1.54 M | ||||
| Retained Earnings | (142.52 M) | ||||
| Working Capital | (5.88 M) | ||||
About OKYO Pharma Performance
By examining OKYO Pharma's fundamental ratios, stakeholders can obtain critical insights into OKYO Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that OKYO Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (258.29) | (245.38) | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) |
Things to note about OKYO Pharma performance evaluation
Checking the ongoing alerts about OKYO Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OKYO Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OKYO Pharma generated a negative expected return over the last 90 days | |
| OKYO Pharma has some characteristics of a very speculative penny stock | |
| OKYO Pharma has high historical volatility and very poor performance | |
| OKYO Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.8 M) with loss before overhead, payroll, taxes, and interest of (3.6 M). | |
| OKYO Pharma Ltd currently holds about 2.06 M in cash with (9.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| OKYO Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing OKYO Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OKYO Pharma's stock is overvalued or undervalued compared to its peers.
- Examining OKYO Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OKYO Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OKYO Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OKYO Pharma's stock. These opinions can provide insight into OKYO Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.